Alligator Bioscience on the latest developments

Only a few weeks into the new year Alligator updated the market on the progression of the phase Ib/II study OPTIMIZE-1, a new research collaboration, and about a new major shareholder joining  Alligator’s nomination committee.

BioStock reached out to CEO Søren Bregenholt to get his view on the latest developments. Immuno-oncology company Alligator Bioscience develops.